https://orcid.org/0000-0001-7913-9328
References
- Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7(1):4–10. doi:10.2174/1874364101307010004
- Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol. 2017;58:102–138.
- Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB. Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells. 2022;11(12):1950. doi:10.3390/cells11121950
- Chakraborty S, Sheth JU. Contralateral effect following intravitreal brolucizumab injection in diabetic macular edema. Case Rep Ophthalmol Med. 2022;2022:3755249.
- Chakraborty D, Sheth JU, Boral S, Sinha TK. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep. 2021;24:101197. doi:10.1016/j.ajoc.2021.101197
- Fraser-Bell S, Kang HK, Mitchell P, Arnold JJ, Tainton J, Simonyi S. Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study. Br J Ophthalmol. 2023;107(1):72–78. doi:10.1136/bjophthalmol-2021-319070
- Sharma A, Sheth J. Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification. Eur J Ophthalmol. 2015;25(3):e5. doi:10.5301/ejo.5000559
- Sharma A, Sheth J, Madhusudan RJ, Sundaramoorthy SK. Effect of intravitreal dexamethasone implant on the contralateral eye: a case report. Retin Cases Brief Rep. 2013;7(3):217–219. doi:10.1097/ICB.0b013e31828993a1
- He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol. 2018;18(1):121. doi:10.1186/s12886-018-0779-1
- Kabanarou SA, Xirou T, Boutouri E, et al. Pre-operative intravitreal dexamethasone implant in patients with refractory diabetic macular edema undergoing cataract surgery. Sci Rep. 2020;10(1):5534. doi:10.1038/s41598-020-62561-3
- Rauen PI, Ribeiro JA, Almeida FP, Scott IU, Messias A, Jorge R. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina. 2012;32(9):1799–1803. doi:10.1097/IAE.0b013e31824bebb8
- Furino C, Boscia F, Niro A, et al. Combined phacoemulsification and intravitreal dexamethasone implant (Ozurdex®) in diabetic patients with coexisting cataract and diabetic macular edema. J Ophthalmol. 2017;2017:4896036. doi:10.1155/2017/4896036
- Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914.
- Pareja-Ríos A, Ruiz-de la Fuente-Rodríguez P, Bonaque-González S, López-Gálvez M, Lozano-López V, Romero-Aroca P. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol. 2018;11(1):77–82. doi:10.18240/ijo.2018.01.14
- Mishra SK, Gupta A, Patyal S, et al. Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous. 2018;4:13.
- Badrinarayanan L, Rishi P, George R, Isaac N, Rishi E; Sankara Nethralaya Vitreo-Retinal group (SNVR). Incidence, risk factors, treatment, and outcome of ocular hypertension following intravitreal steroid injections: a comparative study. Ophthalmologica. 2022;245(5):431–438. doi:10.1159/000522504